International Journal of Medical Toxicology & Legal Medicine Volume 27, No. 5, 2024
e-ISSN: 0974-4614
p-ISSN: 0972-0448
https://doi.org/10.47059/ijmtlm/V27I5/059

Role of Pharmacists and Nurses in Preventing Medication-Related Toxicity in High-Risk Patients

Enaam Mohammed Shbaily[1], Hadeel Mohamed Jaafary[1], Nasser Jaber Moharraq[2], Rehab Hadi Alhkallaf[3], Raneem Sami Alharbi[4], Bashaer Ahmed Elagi[4], Ghayah Abdullah Jabbari[4], Norah Hussain Ali[5],Aisha Suqir Alsufyani[6], Eman Ali Alhumayani[6], Ibrahim Mohammed Dighriri[7]

[1]Department of Pharmacy, Armed Forces Hospital, Jazan, Saudi Arabia.
[2]Department of Pharmacy, Prince Mohammed Bin Nasser Hospital, Jazan, Saudi Arabia.
[3]Department of Pharmacy, Alaqiq General Hospital, Albaha, Saudi Arabia.
[4]Pharmacy College, Jazan University, Saudi Arabia.
[5]Pediatrics Department. King Fahd Hospital, Jazan, Saudi Arabia.
[6]Department of Nursing, King Abdulaziz Specialist Hospital, Taif, Saudi Arabia.
[7]Department of Pharmacy, King Abdulaziz Specialist Hospital, Taif, Saudi Arabia.

Received: 18.09.2024 Revised: 14.10.2024 Accepted: 09.11.2024

ABSTRACT
Drug toxicity continues to be one of the significant issues in healthcare. It is, most of the time, responsible for adverse drug events (ADEs), hospitalizations, morbidity, and mortality among high-risk patients. This broad overview considers the significant collaborative roles that pharmacists and nurses play in the prevention of medication-related toxicity in high-risk populations, comprising older adults, individuals with multiple comorbidities, and patients requiring polypharmacy.It describes the integral aspects of pharmacists' participation in medication therapy management (MTM), clinical pharmacokinetic monitoring, and patient education, as well as nurses' important roles in medication administration, patient monitoring, and early detection of toxicity.Implementing technological solutions, such as clinical decision support systems (CDSS), barcode medication administration (BCMA), and smart infusion pumps, has improved prevention efforts.Challenges include staffing restraints on care fragmentation and the need for more interprofessional training.This research shows that integrated programs, including pharmacist medication reviews and vigilant nursing clinical monitoring, have reduced error rates by up to 50% in other healthcare settings.Integrating personalized medicine approaches, particularly pharmacogenomics, would ensure potential opportunities to optimize medication safety for high-risk populations.According to this study, successfully preventing medication-related toxicity requires a coordinated, multidisciplinary approach, with ongoing investment in research, technology, and workforce development support.

Keywords: Medication-related toxicity, Nurses, High-risk patients, Pharmacists, Interprofessional collaboration, clinical decision support systems, pharmacokinetic monitoring, adverse drug events, medication reconciliation, smart infusion pumps, Pharmacogenomics, Healthcare technology.

1. INTRODUCTION

Drug toxicity is one of the most challenging yet avoidable problems in today's healthcare and usually results in most negative drug events (ADEs), hospitalization, morbidity, and mortality. All high-risk patients, older adults, those with multiple comorbidities, the critically ill, and those requiring polypharmacyare at higher risk for these adverse outcomes because of physiologic vulnerabilities and requisite complex therapeutic regimens. According to the Institute of Medicine (IOM), up to 1.5 million preventable adverse drug events (ADEs) occur in the U.S. every year, which costs billions of extra care dollars and takes a very high personal toll on patients and caregivers. Patterns are similar around the world, which is why the World Health Organization (WHO) has initiated "Medication Without Harm" to achieve a 50% reduction in severe avoidable medication-related harm within five years [1–3].

In healthcare systems, nurses and pharmacists have essential positions in decreasing the possible risks of medication toxicity.Nurses are considered the most vital healthcare team members at the bedside of patients, administer medications, monitor clinical status, and educate patients about medication.Pharmacists have expert

knowledge regarding pharmacotherapy, drug interactions, and all aspects of medication management; their input is essential in identifying, correcting, and preventing medication errors that can cause adverse events.The collaborative participation of these professionals with physicians and other members of interdisciplinary teams can be advantageous in reducing errors related to medications and improving safety outcomes related to patients [3,4].

This article describes how pharmacists and nurses can work together to prevent the toxicities associated with medications in high-risk patients.Risk factors for medication errors are described, and the roles of nurses and pharmacists (different but complementary) are delineated using evidence-based strategies to improve prevention efforts.This study is an attempt to consolidate the information and guidelines available, stressing that multi-professional teamwork, systematic interventions, and monitoring of high-risk patients can drastically reduce medication-related toxicity in this high-risk population.

2. Scope and Definitions of Medication-Related Toxicity

Medication-related toxicity includes all the adverse events induced by pharmaceutical agents.It encompasses adverse drug reactions(ADRs), dose-dependent side effects, and drug-drug interactions, as well as toxicities due to improper management of incorrect dosing of medication or non-adherence.Toxicity is usually considered to have a severe, direct, and pharmacological effect (e.g., nephrotoxicity, hepatotoxicity, neurotoxicity). Still, it is placed in a broader context to express clinically significant harm from medication therapy [5,6].

High-risk patients tend to have a low physiological reserve; thus, they are sensitive to minor deviations in dosing or therapy-related decisions.For example, older adults usually have impaired renal and hepatic functions; therefore, dose adjustments are needed for many commonly prescribed medications.Critically ill patients undergo dynamic changes in their physiology, such as variations in fluid balance, changing metabolic requirements, and concurrent organ dysfunction, which can significantly affect the distribution and effect of drugs.Appropriate risk detection through timely assessment and intervention contributes considerably to the involvement of pharmacists and nurses whose skill sets[5,7,8].

This expanded definition aimsto reduce severe ADRs and optimize therapeutic efficacy and preventable harm. In direct patient care, providers identify early signs of toxicity, such as early confusion or minor laboratory abnormalities, to intervene before life-threatening complications can develop.Increased monitoring, patient-centered education, and interprofessional communication are at the top of preventive strategies for medication-related toxicity[6,8].

3. High-Risk Patients: Key Risk Factors and Contributing to Variables

A set of overlapping characteristics can identify high-risk patients.These include advanced age, chronic kidney disease, hepatic dysfunction, and polypharmacy, as well as multiple comorbidities such as diabetes, heart failure, and cancer, and an impaired ability to manage self-management issues, such as cognitive impairment and low health literacy.Table 1 summarizes the most common risk factors and their associated problems that may increase the likelihood of medication toxicity[7,9,10].

Table 1. Common Risk Factors and Challenges for High-Risk Patients

Risk Factor	**Challenges for Medication Safety**
Advanced age	Altered pharmacokinetics, polypharmacy, cognitive decline
Chronic kidney or liver disease	Decreased medication clearance, narrow therapeutic index drugs become more hazardous
Multiple comorbidities	Complex regimens have a higher chance of drug-drug interactions
Polypharmacy (≥5 medications)	Conflicting therapy goals, unrecognized interactions, side effects
Low health literacy or confusion	Incorrect dosing, nonadherence, misunderstood instructions
Post-operative or critically ill	Rapid physiological changes, increased vulnerability to fluctuations in drug levels
Cancer or immunocompromised states	Altered drug metabolism, heightened risk of infection, potential synergy with cytotoxic medications
Pediatric or neonatal population	Differential metabolism, dosing must be weight-based, higher risk of calculation errors

These challenges illustrate how medication safety should be approached individually for each patient.The early identification of these risk factors can help nurses and pharmacists develop tailored precautionary strategies,

such as cautious dose titration, frequent therapeutic drug monitoring, medication reconciliation, and targeted patient education[9,10].

4. Pharmacists' Role in Preventing Medication-Related Toxicity

4.1 Medication Therapy Management (MTM) and Reconciliation

Pharmacists act as pharmacotherapy guardians.This ensures that medication regimens are evidence-based, safe, and properly aligned with patient conditions.MTM is one of the best practices in this profession. It is a systematic practice that assesses medication regimens, identifies issues, and recommends adjustments to improve efficacy and minimize adverse outcomes[10–12].

Medication reconciliation, which involves reviewing a patient's comprehensive medication list at every transition of care, has significantly decreased discrepancies and harm related to medications.These transitions, which include processes such as hospital admission, inter-unit transfer, and discharge, typically pose especially vulnerable periods wherein incomplete or inaccurate documentation can lead to omissions, duplications, dosing errors, and harmful drug interactions.Because of their specialized training, pharmacists can systematically confirm the appropriateness of dose checks for high-risk interactions and resolve medication conflicts[12,13].

4.2 Clinical Pharmacokinetic Monitoring

In high-risk populations, a "one-size-fits-all" dosing approach is unlikely to be appropriate, particularly for drugs with narrow therapeutic indices (e.g., aminoglycosides, vancomycin, and warfarin).Clinical pharmacists apply their knowledge and skills in pharmacokinetics and pharmacodynamics to individualized dosing practices, perform therapeutic drug monitoring, and modify therapy based on laboratory results and patient-specific factors, including renal and hepatic functions[14,15].Active watching reduces the chances of not treating enough (which causes treatment to fail) and treating too much (which causes harm).By closely monitoring blood levels and how well a person responds to medicine, pharmacists can tweak plans and jump in fast if signs of damage appear.By partnering with nurses, they can obtain quick lab results, essential readings, and side effects reports that help correct dose changes[14–16].

4.3 Patient and Caregiver Education

Pharmacists provide substantial input for educational efforts.During dispensing or discharge, patient counseling is essential to clarify dosing instructions, discuss common side effects, and warn regarding potential red flags that should prompt medical attention.This is particularly true for patients caring for chronic conditions with complex regimens.Teaching family caregivers about geriatric and pediatric populations ensures proper administration techniques for monitoring early warning signs of toxicity and adherence to monitoring protocols.Pharmacists use straightforward language, visual aids, and handouts to bridge health literacy gaps for safer home medication use [16,17].

4.4 Collaborative Practice Agreements and Interdisciplinary Rounds

Many healthcare systems have broadened collaborative practice agreements to allow pharmacists to make changes or modify drug therapies independently under agreed-upon protocols. Such a model emphasizes that the direct input of specialized pharmacist knowledge benefits patient care, primarily for patients who need frequent changes to their medication regimens. The role of pharmacists is further demonstrated through their participation in interdisciplinary rounds.Pharmacists can proactively prevent and mitigate risks by discussing patient cases with physicians, nurses, dietitians, and other team members.This type of real-time input helps close the gap between recognizing a potential problem and taking corrective action promptly[18,19].A recent study published in the Archives of Internal Medicine showed that integrating a clinical pharmacist within an intensive care team resulted in a 66% reduction in preventable ADEs[18–20].

5. Nurses' Role in Preventing Medication-Related Toxicity

5.1 Medication Administration and Error Prevention

Nurses form the "final check" part of the chain of medication administration. They validate the "Five Rights" of medication use: right patient, drug, dose, route, and timebefore dispensing. Due to their proximity to patients, they become very important reviewers who can easily observe and note any developing signs of toxicity and make timely interventions.Nurses often perform extra checks for high-risk drugs.These might include independent double-checks where two nurses confirm the medication, its dose calculation, the patient's identity, barcode scanning, and proper documentation in electronic medication administration records.Such practices reduce the likelihood of errors, which can lead to serious toxicity[20,21].

5.2 Patient Monitoring and Early Recognition of Toxicity

Because they have constant and direct contact with patients, nurses are in an excellent position to notice subtle changes in clinical status that might signal toxicity from medications.An example may involve a slowly

increasing lethargic patient receiving high-dose opioids or initial signs of bleeding in a patient receiving anticoagulation therapy.Routine vital sign monitoring, bedside assessment of neurological status, and subjective complaint reporting allow nurses to alert interdisciplinary team members to emerging risks.Therefore, early detection is imperative in high-risk patients.Nurses can deploy standardized tools and scoring systems, such as sedation scales for opioid-treated patients or checklists for chemotherapy toxicities, to enforce consistent, objective assessments.When identified early, abnormal signs enable rapid intervention by adjusting doses or supportive measures provided by pharmacists and physicians[22,23].

5.3 Patient and Family Education

Pharmacists and doctors provide primary counseling for medications.Nurses reinforce this teaching, either at the bedside or at the clinic.They converted technical information into everyday language and offered practical advice.This will ensure patients know how to take medications, watch for adverse effects, and report them.Teaching self-monitoring practices, such as checking blood pressure at home, monitoring blood glucose levels, and adhering to specific dietary restrictions, enables patients to become involved in their care.Elderly patients, particularly those with language barriers, require such a contact person to clarify questions.It is through their educational role that medication adherence is promoted while unrecognized toxicity at home is minimized[22,24].

5.4 Creating a Culture of Safety and Reporting

Nurses often have the most direct patient contact hours, making their voices essential to the clinical safety culture of institutions.Encouraging near-miss reports and actual medication errors increases the number of learning systems that continuously adapt and improve processes.However, timing mitigates unintentional mistakes or unusual adverse events by reporting immediately, followed by root cause analysis to prevent recurrence.Nurse leaders can join quality improvement initiatives through collective efforts by the pharmacy and medical staff.Perhaps new electronic alerts, revisions of local prescription protocols, or simulation-based training sessions on high-risk medication administration would be appropriate.In this environment, nurses are empowered to ask for unclear orders, suggest safer alternatives, and collaborate with other team members[24,25].

6. Interprofessional Collaboration and Communication

The safety of medication is inherently multidisciplinary.Pharmacists and nurses, though specially empowered to prevent toxicity due to medications, can deliver their full potential only in conjunction with prescribers, allied health professionals, and the patient.Frequent communication and collaborative decision-making help identify risks early, avoid prescribing cascades, and maximize therapeutic decisions for high-risk populations[26,27].

Medication Safety Huddle: One type of collaboration is represented by “safety huddles, which could be daily or weekly, where team members discuss high-risk patients, medication changes, or near-miss incidents.Pharmacists would share relevant updates on pharmacokinetics, and nurses may provide clinical observations at the bedside[27,28].

Joint Education and Training: Cross-training sessions, where nurses learn basic pharmacokinetic principles and pharmacists advance their knowledge of bedside clinical assessments, can help foster a shared understanding.This bidirectional exchange enriches each other’s skill sets and makes patient care more cohesive[28,29].

Electronic Health Record (EHR) Integration: Excellent EHR systems enhance collaboration between various professions. Pharmacists perform some of the system's activities, including inputting clinical notes, documenting dose adjustments, and flagging possible interactions. Nurses readily access these updates and incorporate them into their medication administration responsibilities.Properly designed alerts in EHRs can facilitate real-time communication regarding dosing or lab anomalies, reducing the time delay previously experienced[26,29].

7. Strategies and Tools for Preventing Toxicity

7.1 Clinical Decision Support Systems (CDSS)

Clinical decision support systems (CDSS) embedded within EHRs may significantly reduce medication errors because they prompt automated alerts for drug-drug interactions, excessive dosing, or contraindications related to the renal function.When nurses and pharmacists use the CDSS as intended, it acts as a second verification system, although it is not entirely separate from clinical judgment.It should be noted that the management and updating of CDSS tools should be performed with “alert fatigue” in mind.Too many vague alerts can cause users to pay less attention to important warnings.Thus, institutions need to ensure that their CDSS is designed to meet the needs of high-risk patients so that alerts are both clinically relevant and actionable [30–32].

7.2 Protocols, Pathways, and Checklists

Standardized protocols and pathways are helpful in high-risk situations, such as anticoagulation management, chemotherapy administration, or total parenteral nutrition. Along with physicians, nurses, and pharmacists, they can create simple checklists that include the necessary labs, dosing guidelines, and monitoring requirements.For example, the protocol for warfarin therapy management in older adults incorporates daily international normalized ratio (INR) monitoring for the first few days, structured algorithms for dose adjustment, and bridging therapy guidelines for low-molecular-weight heparin.This helps to reduce variability in care to avoid unintentional toxicity[33,34].

7.3 Barcoding and Smart Infusion Pumps

BCMA and smart infusion pumps have become widely adopted to reduce administration errors in the acute care arena.Nurses used bar-coded medications and patient ID bracelets, verifying that the right drug and dose were administered at the right time.Smart pumps provide an additional safety check by setting maximum and minimum infusion rates for high-alert medications, such as opioids and vasopressors; users are automatically notified if a parameter is exceeded.Pharmacists also participate by ensuring proper drug concentration, dosing limits, and infusion rates for updating the pump libraries.This technological synergy between pharmacy and nursing workflows represents a cornerstone in protecting high-risk populations from miscalculated dosages or inadvertent double pumping of opioids and other high-risk medications[35,36].

8. Implementation Challenges and Potential Solutions

Indeed, numerous obstacles exist that preclude effective pharmacist-nurse collaboration from translating into improved reduction of toxic effects from medications. According to monitoring and education, staffing and time for medication reconciliation would be more than adequate, and care fragmentation across various settings requires standardized communication protocols and pharmacist involvement in discharge planning.In addition, lack of interprofessional training holds collaborative skill development, and underfunding may limit funding for essential technologies, such as CDSS and barcoding. Overreliance on alerts adds to “alert fatigue,” underlining the importance of adjusting system parameters so that only high-priority, clinically relevant warnings reach end-users. Among them are policy advocacy to increase workforce numbers, strong telepharmacy initiatives, interprofessional educational reforms, and thorough cost-effectiveness studies that justify the expansion of pharmacist-nurse services[37–39].

9. Future Directions and Research Gaps

Growing trends in personalized medicine, especially incorporating pharmacogenomic and biomarker data, can considerably optimize the medication safety profile in high-risk populations.In this regard, continuous education on genetic variations, such as CYP450 polymorphisms, is necessary for pharmacists and nurses to lower toxicity risks; labor inputs with real-time possible dose adjustments through point-of-care testing and big analytics could be justified.Henceforth, research funding should be redirected to collaborative frameworks for integrating pharmacogenomics research, such as how pharmacists collaborate with geneticists to provide individualized therapy and leadership of nurses in promoting patient education and sample collection, along with long-term outcome measurements in mortality, healthcare costs, and overall effectiveness.Other advances would relate to artificial intelligence-based alert systems, telemonitoring, and comprehensive cost-effectiveness analyses informing policies and resource allocations thereafter[39–41].

10. CONCLUSION

Preventive measures regarding medication toxicity among high-risk patients involve a coordinated multitasking effort that draws upon the combined talents of pharmacists and nurses as members of the healthcare team.Evidence has shown that when these professionals work as a team, ADEs can be minimized, and patient outcomes can be improved through MTM and pharmacokinetic expertise from the pharmacist and nursing bedside monitoring for early signs of toxicity in the patient.Recent technological advancements in CDSS, BCMA, and infusion pumps have also advanced failure prevention.However, staffing levels, fragmentation of care, and inter-professional collaboration training pose significant challenges to the system.Even so, pharmacogenomics, as a component of personalized medicine, holds great promise in furthering decreased medication toxicity in at-risk populations.Success in this will demand further input into research, technology, and worker training, along with a long-term pledge to build good interprofessional links.As changes occur in healthcare systems, the teamwork model between pharmacists and nurses will remain key to ensuring that medications are safe and that there are best treatment results for high-risk patients.

Author Contributions: All the authors contributed equally to the design and implementation of the study, analysis of the results, and writing of the manuscript.

Conflict of Interest Declaration: The authors declare that they have no affiliations with or involvement in any organization or entity with any financial interests in the subject matter or materials discussed in this manuscript .

Funding Statement: The study did not receive any funding.

REFERENCES

1. Sivasamy V, Yip KF, Mamun K, Lim KW: A review of the effectiveness of interventions to reduce medication errors among older adults in Singapore. Proc Singapore Healthc. 2023, 32:20101058231172230. 10.1177/20101058231172232
2. Tetteh EK: Reducing avoidable medication-related harm: What will it take? Res Soc Adm Pharm. 2019, 15:827–40. 10.1016/j.sapharm.2019.04.002
3. Ash Mohd A, Fatima W, Alanazi FJ, et al.: Role of Pharmacists and Nurses to Avoid Physicochemical Drug Interactions to Ensure Patient Safety. Asian J Pharm. 2024, 18:690.
4. ASHP: Medication Safety-Guidelines ASHP Guidelines on Preventing Medication Errors in Hospitals Purpose. Medicat Safety-Guidelines. 2017, 267–89.
5. Mainoli B, Gonçalves N, Ferreira JJ, Mégarbane B: Potential drug-drug interactions in acute poisonings managed in the intensive care unit: Occurrence, risk factors and relationship to patient severity on admission. Basic Clin Pharmacol Toxicol. 2022, 130:337–45. 10.1111/bcpt.13698
6. Shenfield GM, Jacka J: Adverse drug reactions. Lancet. 2001, 357:561. 10.1016/S0140-6736(05)71713-X
7. Edwards IR, Aronson JK: Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000, 356:1255–9. 10.1016/S0140-6736(00)02799-9
8. McDermid RC, Bagshaw SM: Physiological Reserve and Frailty in Critical Illness. Oxford University Press; 2014. 10.1093/med/9780199653461.003.0028
9. Nobili A, Garattini S, Mannucci PM: Multiple Diseases and Polypharmacy in the Elderly: Challenges for the Internist of the Third Millennium. J Comorbidity. 2011, 1:28–44. 10.15256/joc.2011.1.4
10. Coelho F, Furtado L, Mendonça N, et al.: Predisposing Factors to Medication Errors by Nurses and Prevention Strategies: A Scoping Review of Recent Literature. Nurs Reports. 2024, 14:1553–69. 10.3390/nursrep14030117
11. American College of Clinical Pharmacy: What is Medication Therapy Management (MTM)? • A range of services provided to individual patients to optimize therapeutic outcomes (help patients get the most benefit from their medications) and detect and prevent costly medication problems. Leadersh Medicat Manag.
12. Barnsteiner JH: Medication Reconciliation. 2008.
13. Alghamdi DS, Alhrasen M, Kassem A, et al.: Implementation of medication reconciliation at admission and discharge in Ministry of Defense Health Services hospitals: A multicentre study. BMJ Open Qual. 2023, 12:. 10.1136/bmjoq-2022-002121
14. Alsultan A, Alghamdi WA, Alghamdi J, et al.: Clinical pharmacology applications in clinical drug development and clinical care: A focus on Saudi Arabia. Saudi Pharm J. 2020, 28:1217–27. 10.1016/j.jsps.2020.08.012
15. Francis J, Abraham S: Clinical pharmacists: Bridging the gap between patients and physicians. Saudi Pharm J. 2014, 22:600–2. 10.1016/j.jsps.2014.02.011
16. Saqr M, Mawdah AL, Saeed A, Alalhareth A, Khalaf H: The Role of Pharmacists in Enhancing Patient Education and Access to Specialty Medications. 2024, 7:483–8.
17. Ali S, Shimels T, Bilal AI: Assessment of Patient Counseling on Dispensing of Medicines in Outpatient Pharmacy of Tikur-Anbessa Specialized Hospital, Ethiopia. Ethiop J Health Sci. 2019, 29:727–36. 10.4314/ejhs.v29i6.9
18. Awdishu L, Singh RF, Saunders I, et al.: Advancing Pharmacist Collaborative Care within Academic Health Systems. Pharmacy. 2019, 7:142. 10.3390/pharmacy7040142
19. Alkhateeb FM, Unni E, Latif D, Shawaqfeh MS, Al-Rousan RM: Physician attitudes toward collaborative agreements with pharmacists and their expectations of community pharmacists' responsibilities in West Virginia. J Am Pharm Assoc. 2009, 49:797–800. 10.1331/JAPhA.2009.08111
20. Nanji K, Cina J, Patel N, Churchill W, Gandhi T: Overcoming Barriers to the Implementation of a Pharmacy Bar Code Scanning System for Medication Dispensing: A Case Study. J Am Med Inform Assoc. 2009, 16:645–50. 10.1197/jamia.M3107
21. Institute for Safe Medication Practices Canada: Medication Bar Code System Implementation Planning Section II: Building the Case for Automated Identification of Medications Canadian Pharmaceutical Bar Coding Project (Final). Inst fo Safe Medicat Pract Canada. 2013, 2013:.
22. Jordan S, Tunnicliffe C, Sykes A: Minimizing side-effects: The clinical impact of nurse-administered 'side-effect' checklists. J Adv Nurs. 2002, 37:155–65. 10.1046/j.1365-2648.2002.02064.x
23. Alshehry AS: Attitude toward vital signs monitoring and its predictors among clinical nurses in Saudi Arabia. Front Public Heal. 2024, 12:1454851. 10.3389/fpubh.2024.1454851
24. Hawkins B: ASHP Guidelines on Pharmacist-Conducted Patient Education and Counseling. Best Pract.

2024, 421–4. 10.37573/9781585287048.058
25. Abdelaliem SMF, Alsenany SA: Factors Affecting Patient Safety Culture from Nurses' Perspectives for Sustainable Nursing Practice. Healthc (Basel, Switzerland). 2022, 10:. 10.3390/healthcare10101889
26. Zaij S, Pereira Maia K, Leguelinel-Blache G, Roux-Marson C, Kinowski JM, Richard H: Intervention of pharmacist included in multidisciplinary team to reduce adverse drug event: a qualitative systematic review. BMC Health Serv Res. 2023, 23:927. 10.1186/s12913-023-09512-6
27. Wilbur K, Scarborough K: Medication Safety Huddles: Teaming Up to Improve Patient Safety. Can J Hosp Pharm. 2005, 58:. 10.4212/cjhp.v58i3.307
28. Abbasi Nazari M, Salamzadeh J, Hajebi G, Gilbert B: The role of clinical pharmacists in educating nurses to reduce drug-food interactions (absorption phase) in hospitalized patients. Iran J Pharm Res IJPR. 2011, 10:173–7.
29. Vos JFJ, Boonstra A, Kooistra A, Seelen M, Van Offenbeek M: The influence of electronic health record use on collaboration among medical specialties. BMC Health Serv Res. 2020, 20:676. 10.1186/s12913-020-05542-6
30. Kuperman GJ, Bobb A, Payne TH, et al.: Medication-related clinical decision support in computerized provider order entry systems: a review. J Am Med Inform Assoc. 2007, 14:29–40. 10.1197/jamia.M2170
31. Dort B, Zheng W, Baysari M: Prescriber perceptions of medication-related computerized decision support systems in hospitals: A synthesis of qualitative research. Int J Med Inform. 2019, 129:. 10.1016/j.ijmedinf.2019.06.024
32. Huibers L: Clinical decision support-assisted pharmacotherapy optimisation for older hospitalised patients.
33. Guenter P, Worthington P, Ayers P, et al.: Standardized Competencies for Parenteral Nutrition Administration: The ASPEN Model. Nutr Clin Pract Off Publ Am Soc Parenter Enter Nutr. 2018, 33:295–304. 10.1002/ncp.10055
34. Witt DM, Clark NP, Kaatz S, Schnurr T, Ansell JE: Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. J Thromb Thrombolysis. 2016, 41:187–205. 10.1007/s11239-015-1319-y
35. Mulac A, Mathiesen L, Taxis K, Gerd Granås A: Barcode medication administration technology use in hospital practice: a mixed-methods observational study of policy deviations. BMJ Qual Saf. 2021, 30:1021–30. 10.1136/bmjqs-2021-013223
36. Barakat S, Franklin BD: An Evaluation of the Impact of Barcode Patient and Medication Scanning on Nursing Workflow at a UK Teaching Hospital. Pharm (Basel, Switzerland). 2020, 8:. 10.3390/pharmacy8030148
37. Feldman LS, Costa LL, Feroli ER, et al.: Nurse-pharmacist collaboration on medication reconciliation prevents potential harm. J Hosp Med. 2012, 7:396–401. 10.1002/jhm.1921
38. Wakob I, Schiek S, Bertsche T: Overcoming Barriers in Nurse-Pharmacist Collaborations on Wards – Qualitative Expert Interviews with Nurses and Pharmacists. J Multidiscip Healthc. 2023, 16:937–49. 10.2147/JMDH.S408390
39. Sadee W, Wang D, Hartmann K, Toland AE: Pharmacogenomics: Driving Personalized Medicine. Pharmacol Rev. 2023, 75:789–814. 10.1124/pharmrev.122.000810
40. Goetz LH, Schork NJ: Personalized medicine: motivation, challenges, and progress. Fertil Steril. 2018, 109:952–63. 10.1016/j.fertnstert.2018.05.006
41. Molla G, Bitew M: Revolutionizing Personalized Medicine: Synergy with Multi-Omics Data Generation, Main Hurdles, and Future Perspectives. Biomedicines. 2024, 12:. 10.3390/biomedicines12122750